Penicillin Prophylaxis in Sickle Cell Disease (PROPS)
Launched by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) · Oct 27, 1999
Trial Information
Current as of January 15, 2025
Completed
Keywords
ClinConnect Summary
BACKGROUND:
For over 20 years children with sickle cell anemia have been known to have an increased susceptibility to severe bacterial infection, particularly due to Streptococcus pneumoniae. Meningitis, pneumonia and septicemia due to this organism have been recognized as the major causes of death for these children, with children under three years of age being at highest risk. The annual incidence of pneumococcal septicemia among young children with sickle cell anemia appears to have remained remarkably constant over the last two decades at approximately 10 percent. This illness can ofte...
Gender
ALL
Eligibility criteria
- • In the Phase I trial, Black children with sickle cell anemia aged 3 months to 3 years. In the Phase II trial, children with sickle cell anemia aged five years 3 months of age and younger who had received prophylactic penicillin for at least two yea
Trial Officials
David Becton
University of Arkansas
Ann Bjornson
Gamble Institute of Medical Research
George Buchanan
University of Texas
Neil Grossman
Children's Hospital Medical Center, Cincinnati
C. Holbrook
East Carolina University School of Medicine
Rathyi Iyer
University of Mississippi Medical Center
Karen Kalinyak
Children's Hospital Medical Center, Cincinnati
Thomas Kinney
Duke University
Helen Maurer
University of Illinois at Chicago
Scott Miller
New York Health Science Center
Charles Pegelow
University of Miami
Sergio Piomelli
Columbia University
Gregory Reaman
Children's Hospital National Medical Center
Alan Schwartz
Washington University School of Medicine
Elliott Vichinsky
Children's Hospital & Medical Center
Winfred Wang
St. Jude Children's Research Hospital
Doris Wethers
St. Luke's Roosevelt Institute of Health Science
Gerald Woods
Children's Mercy Hospital Kansas City
About National Heart, Lung, And Blood Institute (Nhlbi)
The National Heart, Lung, and Blood Institute (NHLBI) is a leading component of the National Institutes of Health (NIH), dedicated to advancing research and clinical trials focused on cardiovascular, pulmonary, and hematologic diseases. With a mission to improve public health through innovative research, the NHLBI supports a wide range of studies aimed at understanding, preventing, and treating heart and lung conditions. By collaborating with academic institutions, healthcare providers, and patient communities, the NHLBI strives to translate scientific discoveries into effective clinical practices, ultimately enhancing the quality of life for individuals affected by these critical health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials